🔴 Moderna is trading 4.5% down today after norovirus vaccine failure and Q2 earnings

Moderna is trading 4.5% down at $55.30 after the company reported Q2 2026 earnings and a clinical setback for its norovirus vaccine candidate.

• The company beat revenue expectations with $145 million and reported a narrower-than-expected loss per share.
• Investor sentiment was dampened by news that the norovirus candidate mRNA-1403 failed to meet its statistical goals in clinical trials.
• Management reiterated its 2026 revenue growth guidance despite the pipeline challenges.